Swedish biotech company Alligator Bioscience announced a collaboration with Orion Corporation, a Finnish pharmaceutical firm, to discover and develop bispecific antibody cancer therapeutics.
Under the terms of the research collaboration and licensing agreement struck by the two firms, Orion will identify immune-oncology targets for bispecific antibody cancer therapeutics. Whereas, the candidates will next be developed using Alligator's phage display libraries and RUBY bispecific antibody technology.
During the research phase of the deal, Alligator will receive an upfront payment and research support payments and is also eligible for development, approval, and sales milestone payments totaling up to €469 million (USD 548 million). It may also receive royalties if Orion decides to continue developing and commercializing the bispecific antibody candidates.
Outi Vaarala, Senior Vice President, R&D, Orion, stated that they are thrilled about the collaboration and development of new immuno-oncology treatments that will mobilize the immune system to kill cancer cells. Bispecific antibodies offer various advantages for next-generation immuno-oncology treatments, such as increased efficacy, particularly in cancer patients who did not benefit from the available therapies, she added.
Søren Bregenholt, CEO of Alligator Bioscience, mentioned that this collaboration would combine their experience in immuno-oncology development and antibody discovery with Orion's understanding of novel immuno-oncology techniques.
He further stated that this agreement demonstrates that Alligator Bioscience's broad portfolio of phage display libraries, along with RUBY bispecific technology, provides a strong basis for identifying and developing high-quality first-in-class therapeutic antibodies with
About Alligator Bioscience
Alligator Bioscience is a clinical-stage biotechnology company that develops antibody-based medications for cancer treatment. The company specializes in tumor-directed immunotherapies, mainly agonistic mono- and bispecific antibodies, and is involved in the initial stages of drug development, from concept to clinical phase II trials.
Source Credits –